Axicabtagene Ciloleucel
Refractory Non-Hodgkin Lymphoma
Lyell Immunopharma, Inc.Cell therapyPhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 55/ 100
- Competitive Position
- 89/ 100
Competitive context
12 Active assets in the Refractory Non-Hodgkin Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Olaparib OHSU Knight Cancer Institute | Phase 2 | BB |
Vesanoid Rita Assi | Phase 2 | B |
VEMURAFENIB OHSU Knight Cancer Institute | Phase 2 | B |
cd19/22 cart The First Affiliated Hospital of Soochow University | Phase 2 | B |
Pyrotinib The First Affiliated Hospital of Soochow University | Phase 2 | B |
View all 16 →
Same molecule, other indications
Axicabtagene Ciloleucel is also rated in:
Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell LymphomaDormant
BBB
Indicative ·
77 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →